AgomAb Therapeutics (NASDAQ:AGMB) Rating Increased to Strong-Buy at Piper Sandler

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by equities researchers at Piper Sandler to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $60.00 target price on the stock. Piper Sandler’s target price indicates a potential upside of 327.96% from the stock’s current price.

Several other analysts also recently issued reports on the company. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating on the stock. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Price Performance

Shares of AGMB opened at $14.02 on Tuesday. The stock’s 50 day simple moving average is $13.02. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that AgomAb Therapeutics will post -1.71 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.